Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
2 investors
Promentis Pharmaceuticals is a privately-held biopharmaceutical company developing oral compounds targeting the System xc- glutamate pathway to treat neuropsychiatric disorders. Its lead indication is trichotillomania, and its work extends to other obsessive-compulsive, addictive, and CNS conditions.
2 investors
2 investors
Protagonist is a company that emphasizes a diverse and inclusive corporate culture as central to its innovation, with stated goals of creating wins for its organization and for patients.
2 investors
Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones. Its work targets patients affected by protein misfolding disorders.
2 investors
Proteina develops single-molecule protein-protein interaction (PPI) detection technology (SPID) that generates real-time, high-resolution data to support therapeutic drug development. The company applies PPI analysis toward precision medicine.
2 investors
Protein Distillery makes Prewtein, a yeast-based clean-label protein ingredient with high protein content and functional properties like gelation, solubility, and emulsification. The non-GMO, non-novel ingredient is used to reduce additives and replace animal-based ingredients such as eggs in food products.
2 investors
ProteoWise develops the Hyperblot benchtop instrument for high-throughput multiplexed proteomics, letting researchers load samples and antibody panels to obtain quantified western-style protein data. It targets life-science researchers working in areas such as neuroscience, cancer, and immunology.
2 investors
ProTgen is a clinical-stage biotechnology company developing targeted Notch activators that generate progenitor T cells to restore thymic function and adaptive immune competence. Its work spans ex vivo cell therapy (ProT-096) and in vivo biologic programs (RGT-096).
2 investors
Prothea Technologies develops fluorescence imaging and optical sensing technologies for respiratory medicine and oncology applications. The company creates medical devices and diagnostic platforms focused on advancing clinical validation and regulatory approval for respiratory and cancer care.
2 investors
Protillion Biosciences develops platform technology for antibody engineering and drug discovery.
2 investors
Provolut offers an AI-based web app for protein design that predicts protein evolutions and generates candidate variants from a client's starting dataset, aiming to achieve target protein attributes with far fewer lab experiments than methods like directed evolution or deep mutational scanning. It serves pharma, biotechnology, and research organizations, with on-premises or API deployment options.
2 investors
Proxima is a biotech company developing proximity therapeutics through a drug discovery engine and a structural proteomics data platform.
2 investors
Psilera is a biotech company developing neuroscience-focused therapeutics, including its lead asset PSIL-006, described as next-generation mindful medicine.
2 investors
PsiThera is a biotechnology company using computational and physics-based methodsβincluding quantum mechanics, molecular dynamics, machine learning, and simulationβfor mechanism-driven drug design and discovery. Its work spans computational chemistry, immunology, and translational research to advance novel therapeutics.
2 investors
Psygen is a licensed manufacturer of pharmaceutical-grade psychedelic active pharmaceutical ingredients for academic research, clinical trials, and authorized medical use. The company serves researchers, physicians, and healthcare systems working within regulated compassionate-use and special access programs.
2 investors
Psilocybin biosynthesis platform that produces psychoactive molecular entities using yeast-based technology for pharmaceutical research and drug development.
2 investors
2 investors
PTM Therapeutics is a biotechnology company developing therapeutic candidates. The page does not provide sufficient detail about the company's specific focus areas or customer markets.
2 investors
PulseSight Therapeutics develops non-viral, plasmid-based gene therapies delivered via a proprietary electro-transfection system into the ciliary muscle to treat severe retinal diseases causing blindness. Its lead programs target late-stage dry AMD/geographic atrophy and wet AMD, with prior Phase 1/2 studies conducted in Europe and the USA.
2 investors
Pumpkinseed builds a nanophotonic chip platform that reads proteins directly at single-molecule resolution using Raman spectroscopy, generating structured proteomic data. Its technology serves biopharma, biosecurity, and bio-AI applications, aiming to make the proteome readable for drug discovery, biomarker detection, and AI training datasets.
2 investors
PureSpectrum offers a market research technology platform, centered on its PureSpectrum Experience (PSX), that connects people, technology, and quality to support the research workflow for research stakeholders.
2 investors
Purespring develops genetic therapies targeting podocytes to treat renal diseases through its proprietary GlomThera platform. The company focuses on preserving kidney function in patients with large, underserved populations affected by renal disease.
2 investors
Pykus Therapeutics is a clinical-stage medical technology company developing biodegradable polymers for vitreoretinal surgery. Its lead product, PYK-2101, is a biodegradable hydrogel intended to help patients recover from retina surgery faster and more comfortably.
2 investors